Trade Vir Biotechnology VIR

Sell
 Buy

VirBiotechnology live chart

5m 15m 30m 1h 4h 1d 1w

Instrument Fundamentals

Weekly Search
Weekly
Daily
Date Close Change Change (%) Open High Low

VirBiotechnology news

Latest news

Show more
Noah Lee 2025 Aug 07, 15:20

Waller Emerges as Potential Fed Chair Nominee Amidst Trump Considerations

Emma Rose 2025 Aug 07, 14:20

US Jobless Claims Rise: Analyzing Labor Market Trends and Economic Impact

Noah Lee 2025 Aug 07, 13:20

Trump-Putin Talks Fuel Ukraine Asset Rally Amid Peace Hope

Noah Lee 2025 Aug 07, 11:20

Netanyahu Seeks Approval for Full Israeli Occupation of Gaza: Implications and Analysis

Noah Lee 2025 Aug 07, 09:20

The Dollar Squeeze: How Rate Cuts Impact International Investors

Sophia Claire 2025 Aug 07, 09:20

Putin and Trump Meeting Possible Next Week Amid Ukraine Tensions: Kremlin

Noah Lee 2025 Aug 07, 06:20

Bank of England Expected to Cut Rates Amid Inflation Concerns and Slowing Growth

Ava Grace 2025 Aug 07, 05:20

Israel Gaza Conflict: Is a New Offensive on the Horizon?

Info

Spread

0.03

Spread (%)

0.7026 %

Leverage

1:10

Overnight Interest Buy

-0.0597 %

Overnight Interest Sell

-0.0292 %

Currency

USD

Trading Hours

Markets closed

Friday

13:31 - 19:59

Monday

13:31-19:59

Tuesday

13:31-19:59

Wednesday

13:31-19:59

Thursday

13:31-19:59

Analysis and statistics

Open

---

Previous Close

---

52 Week High/Low

--- – ---

Market cap

706394304

Shares Outstanding

138238000

Earnings Date (Next)

0000-00-00

Div Yield

Ex-Dividend Date

Forward annual dividend rate

0

Forward annual dividend yield

0

EPS

-4.23

Learn more about this instrument

Vir Biotechnology Vir Biotechnology Inc
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). It has grant agreements with Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
Markets.com Bonus Trading

Related Instruments

Asset
Sell
Buy
Change (%)

Trade Now

Trade Now

Trade Now

Trade Now
View all instruments

Latest Education Articles

Show more
Trustpilot